Debiopharm International Sa
Clinical trials sponsored by Debiopharm International Sa, explained in plain language.
-
New hope for fighting aggressive brain tumors
Disease control Recruiting nowThis study is testing a new drug called Debio 0123 for adults with glioblastoma, a fast-growing brain cancer. The goal is to see if adding this drug to standard chemotherapy (temozolomide) and radiation is safe and can help control the cancer better. The research will first find …
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New prostate cancer injection aims to simplify hormone therapy
Disease control Recruiting nowThis study is testing a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The goal is to find the best dose that safely lowers testosterone levels to help control cancer growth. Researchers will measure how the drug moves through the body and how …
Phase: PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Experimental drug offers hope for leukemia patients out of options
Disease control Recruiting nowThis early-stage trial is testing a new drug called Debio 1562M for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The study aims to find a safe dose and see if the drug can reduce or eliminate leukemia cells. Participants will…
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New cancer drug combo enters first human trials
Disease control Recruiting nowThis early-stage study is testing a new oral drug called lunresertib, both alone and in combination with two other experimental drugs, for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe dose levels, understan…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New 3-Month shot tested for rare hormone disorder
Disease control Recruiting nowThis study is testing a new, long-acting injection called Debio 4126 for people with acromegaly, a rare hormonal disorder. The goal is to see if one shot every 12 weeks can keep a key hormone (IGF-1) at a safe level, compared to a placebo. It will also check the safety and side e…
Phase: PHASE3 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Mar 02, 2026 15:29 UTC
-
First human doses given in early drug safety trial
Knowledge-focused Recruiting nowThis is a very early-stage study to check the safety and see how a new oral drug, Debio 1453P, moves through the body of healthy adults. The main goal is to find out what side effects might occur and how the body absorbs and eliminates the drug at different dose levels. It does n…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC